Core Viewpoint - The company Huashitong plans to sell its subsidiary Jiangsu Huashitong Biopharmaceutical Technology Co., Ltd. to Kelun Pharmaceutical for 11.75 million RMB, aiming to optimize resource allocation and enhance its strategic planning in the pharmaceutical sector [1][2]. Company Summary - Huashitong is a CDMO (Contract Development and Manufacturing Organization) that provides pharmaceutical intermediates, active pharmaceutical ingredients, and technical services, while also engaging in the research, production, and sales of innovative and generic drugs [1][2]. - Jiangsu Huashitong has total assets of 12.53 million RMB and net assets of 11.41 million RMB as of April 30 this year, with a revenue of 2.24 million RMB and a net profit of 1.05 million RMB in the first four months of the year [2]. Industry Summary - The number of B-license companies has surged from 140 in January 2021 to 1,249 by the end of 2024, indicating a rapid growth in the sector [3]. - B-license companies are characterized by a small scale and a light asset operation model, which has become increasingly common in the context of rising production costs and regulatory scrutiny [3][4]. - Recent regulatory changes have tightened the requirements for B-license companies, limiting their ability to outsource production and emphasizing the need for compliance with Good Manufacturing Practices (GMP) [4].

Core Viewpoint - The dividend performance of listed companies in Sichuan has shown significant improvement, characterized by increased dividend payout ratios, stable dividend amounts, and the gradual establishment of a normalized dividend mechanism, enhancing investment value [1][2]. Group 1: Dividend Payout Ratio - The annual dividend payout ratio for Sichuan-listed companies reached 50.28%, an increase of 7.02 percentage points from the previous year. Approximately 40% of the 43 companies had a payout ratio exceeding 50%, indicating a strong commitment to shareholder returns [1]. Group 2: Stability of Dividend Amounts - Despite some companies facing performance pressures, 105 Sichuan-listed companies announced a total cash dividend of 57.766 billion yuan in 2024, maintaining the same level as the previous year, even with a decrease in profitable companies. Notably, some companies with negative net profits still distributed dividends, reflecting their focus on investor relations [1]. Group 3: Leading Role of Major Companies - In 2024, seven Sichuan-listed companies distributed dividends exceeding 1 billion yuan each, collectively contributing about 43 billion yuan, which accounts for 74% of the total dividend amount [2]. Group 4: Performance of Newly Listed Companies - Over 60% of the 20 newly listed companies in the past three years introduced cash dividend plans for 2024, with an average payout ratio exceeding 50%. Six of these companies executed multiple dividend distributions within the year [2]. Group 5: Normalized Dividend Mechanism - A total of 27 companies increased their frequency of dividend payments by 285% year-on-year, with over 12 billion yuan distributed before the Spring Festival. Additionally, 61 companies have maintained continuous dividends for five years, and 53 companies have disclosed long-term return plans or sought shareholder approval for mid-term dividend strategies [2].

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4][54]. Core Viewpoints - The report highlights that the AD (Alzheimer's Disease) treatment sector is expected to see significant advancements, with a recommendation to focus on companies like Tonghua Jinma and Dongcheng Pharmaceutical [3][9]. - The report emphasizes the importance of innovation, international expansion, and the aging population as key themes driving the industry forward [22][43]. - The pharmaceutical index has shown a positive performance, with a 1.40% increase from June 9 to June 13, outperforming the CSI 300 index by 1.66% [5][22]. Summary by Sections 1. AD Treatment Developments - The report notes that Alzheimer's Disease (AD) is a major global health challenge, with 51.62 million cases worldwide in 2019, including 13.14 million in China [9][10]. - The innovative oral drug, Succinyl-8-hydroxy-aminoguanidine, developed by Tonghua Jinma, has shown promising results in clinical trials and is expected to be a significant player in the AD treatment market [5][21]. 2. Industry Perspectives - The report indicates that the pharmaceutical sector is transitioning from traditional growth drivers to innovative solutions, with a focus on domestic innovation and international market expansion [22][43]. - The aging population is driving demand for chronic disease treatments, and the report suggests that the healthcare payment system is evolving to support this growth [41][43]. 3. Market Performance - The report provides a detailed analysis of stock performance, noting that 218 stocks increased in value while 263 decreased during the reporting period [5][22]. - Specific stocks such as Yiming Pharmaceutical and Sai Sheng Pharmaceutical have shown significant gains, while others like Renmin Tongtai have experienced notable declines [25][26]. 4. Investment Recommendations - The report recommends focusing on innovative pharmaceutical companies and those with strong international expansion capabilities, such as Heng Rui Pharmaceutical and Keren Pharmaceutical [43][44]. - It also highlights the importance of investing in sectors related to aging and outpatient consumption, suggesting companies like Kunming Pharmaceutical and Yuyue Medical [44].

Group 1 - Company GuoDeWei plans to repurchase shares with a total investment of between 100 million to 150 million yuan, with a maximum repurchase price of 53 yuan per share, expecting to buy back between 1.89 million to 2.83 million shares, accounting for 0.78% to 1.17% of total share capital [1] - Company Shuangliang Energy has won a bid for the Gansu Energy Chemical Qinyang 2×660MW coal power project, with a total bid amount of 237 million yuan, representing 1.82% of the company's projected revenue for 2024 [1] - Company China Pacific Insurance reported a total premium income of 227.17 billion yuan from its two subsidiaries in the first five months, with a year-on-year growth of 10.2% for its life insurance subsidiary and 0.5% for its property insurance subsidiary [1][2] Group 2 - Company LuKang Pharmaceutical has received a drug registration certificate for injectable Cefoperazone Sodium, a third-generation cephalosporin with broad-spectrum antibacterial properties [3] - Company 吉祥航空 reported a 4.97% year-on-year increase in passenger turnover in May, with a seat occupancy rate of 86.14%, up 3.70% year-on-year [4][5] - Company DuRui Pharmaceutical's subsidiary has also received a drug registration certificate for injectable Cefoperazone Sodium [6] Group 3 - Company KeLan Software announced that part of the shares held by its controlling shareholder will be auctioned, involving 5.09 million shares, accounting for 1.07% of the total share capital [7] - Company HuaCan Optoelectronics received a government subsidy of 87.84 million yuan, which is expected to positively impact the company's pre-tax profit for 2025 [8] - Company JinZhi Technology has won a bid for projects from the State Grid and China Resources New Energy, with a total bid amount of 84.41 million yuan [9] Group 4 - Company Vision China completed a capital increase for its subsidiary, raising 100 million yuan to accelerate its layout in the AI field [11] - Company Youa Co. received a profit distribution of 96.03 million yuan from its investment in Changsha Bank [13] - Company WanBangde's subsidiary obtained a patent for a deuterated compound, enhancing the chemical stability and reducing toxicity [16] Group 5 - Company DongCheng Pharmaceutical completed the enrollment of all 488 participants in the Phase III clinical trial for Fluorine-18 PSMA peptide injection, aimed at prostate cancer diagnosis [17] - Company China Merchants Expressway announced that its first phase of medium-term notes for 2024 will pay interest on July 2, 2025, with a total issuance of 2.5 billion yuan and an interest rate of 2.35% [18] - Company JinPu Titanium's subsidiary has temporarily suspended production for maintenance due to falling product prices and high production costs [20] Group 6 - Company BeiLu Pharmaceutical received a marketing authorization for Iodinated Contrast Injection in Hungary, marking another approval in the EU [22] - Company LiXing Co. obtained an overseas investment certificate for its wholly-owned subsidiary in Singapore, with a total investment of 2.16 million yuan [24] - Company LangKun Technology won a garbage collection service project with a bid amount of 21.57 million yuan [26] Group 7 - Company KeRui International plans to transfer 55% of its subsidiary Tianjin ZhiRui's equity for 41.96 million yuan [28] - Company Nanjing JuLong intends to invest 130 million yuan to build a production project for special materials with an annual output of 40,000 tons [30] - Company NanShan Intelligent plans to use up to 50 million yuan of idle funds for cash management in safe and liquid financial products [32] Group 8 - Company GuangLian Aviation completed the business change registration for its subsidiary, involving the introduction of strategic investors [34] - Company XiaoFang Pharmaceutical signed a cooperation agreement to develop a new drug for hair loss treatment [36] - Company GuiZhou SanLi plans to sign a 150 million yuan technology transfer and development contract with Guangdong Pharmaceutical University [38] Group 9 - Company ST SiLong's subsidiary received a drug registration certificate for Famotidine injection, used for treating upper gastrointestinal bleeding [52] - Company ZhongKe Information's executive plans to reduce holdings of up to 180,000 shares, accounting for 0.06% of total share capital [53] - Company KeLun Pharmaceutical's injectable Cefoperazone Sodium/Chloride Sodium injection received drug registration approval [54] Group 10 - Company LuXin Investment plans to transfer 10.06% of its stake in LuXin HuiJin for 203 million yuan, aiming to focus on its main business [56] - Company Western Gold plans to acquire 100% of Xinjiang MeiSheng for 1.655 billion yuan [58] - Company JinTou City Development intends to swap assets worth 5.862 billion yuan, changing its main business to urban centralized heating [60]

Policy Developments - The National Health Commission of China is taking measures to ensure blood supply in key areas and important time periods due to a noticeable decline in voluntary blood donations, influenced by factors such as aging population and lifestyle changes [2] - In 2024, the total blood supply in China is expected to decrease year-on-year, with a cumulative blood allocation of 3.613 million units, including 583,000 units allocated between provinces, representing a 35.1% increase [2] Drug and Medical Device Approvals - Kelun Pharmaceutical announced that its subsidiary has received drug registration approval for "Cefazolin Sodium/ Sodium Chloride Injection," which is packaged in a dual-chamber bag and is suitable for emergency treatment [4] - *ST Sailong's subsidiary has obtained a drug registration certificate for Famotidine Injection, classified as a Category A drug under the national medical insurance list, primarily used for treating upper gastrointestinal bleeding [5] Capital Market Activities - Borui Pharmaceutical plans to invest 20 million yuan to subscribe to the increased registered capital of Geek Gene Technology, acquiring a 4.1667% stake in the company [7] Industry Developments - Eli Lilly announced the launch of the multi-dose prefilled pen for Tirzepatide Injection in China, aimed at addressing the needs of the growing number of diabetes and obesity patients [9] - The adult overweight rate in China is 34.3%, with an obesity rate of 16.4%, highlighting the increasing demand for weight management treatments [9] - In the first quarter of this year, Tirzepatide contributed $6.15 billion in revenue to Eli Lilly, accounting for approximately 48% of the company's total revenue [10] - Hanyu Pharmaceutical has completed the enrollment of all subjects for the Phase III clinical trial of Semaglutide Injection for weight management, currently in the follow-up phase [11] Shareholder Actions - Nine Strong Bio's major shareholder completed a share reduction plan, reducing their holdings from 30,969,636 shares to 30,769,636 shares, a decrease from 5.30% to 5.26% of voting shares [13] - Yifeng Pharmacy's controlling shareholder plans to reduce their stake by up to 2%, amounting to no more than 24,248,336 shares [14]

四川科伦药业股份有限公司 证券代码：002422 证券简称：科伦药业 公告编号：2025-050 关于公司注射用头孢唑林钠/氯化钠注射液获得药品注册批准的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误 导性陈述或者重大遗漏负连带责任。 四川科伦药业股份有限公司（以下简称"公司"）子公司湖南科伦制药有限 公司的化学药品"注射用头孢唑林钠/氯化钠注射液"于近日获得国家药品监督 管理局的药品注册批准，现将相关情况公告如下： 一、 药品基本情况 1. 药品名称：注射用头孢唑林钠/氯化钠注射液 剂型：注射剂 规格：粉体室：按头孢唑林（C14H14N8O4S3）计1.0g；液体室：氯化钠注射液 100ml：0.9 g 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 2. 药品相关情况 粉液双室袋是国际上先进的输液产品，其中粉体和液体分别位于两个独立的 腔室，保证混合前各腔室药品的稳定性，临床使用时即开、即混、即用，可有效 避免配制过程中的错配和污染风险，同时节约配制时间、减少配制工作量并降低 医护人员暴露风险，尤其 ...

Core Viewpoint - Kolun Pharmaceutical (002422) announced that its subsidiary, Hunan Kolun Pharmaceutical Co., Ltd., has received drug registration approval from the National Medical Products Administration for its chemical drug "Cefazolin Sodium/Sodium Chloride Injection" [1] Group 1 - The drug is packaged in a dual-chamber bag, containing 1.0g of cefazolin and 0.9g of sodium chloride in 100ml of injection solution [1] - The dual-chamber bag design helps to avoid mismatching and contamination risks during the preparation process, making it suitable for rapid treatment in emergency situations [1] - Cefazolin sodium is a classic medication for infection treatment, with projected sales of 1.35 billion yuan for injection forms in China in 2024 [1] Group 2 - Kolun Pharmaceutical is the second company in China to receive approval for the dual-chamber bag packaging format [1]

四川科伦药业股份有限公司（以下简称"公司"）于2025年6月5日发布了《四 川科伦药业股份有限公司关于控股子公司科伦博泰根据一般性授权配售股份的 公告》（公告编号：2025-046，以下简称"配售公告"），内容有关公司控股子 公司四川科伦博泰生物医药股份有限公司（以下简称"科伦博泰"）与配售代理 签订配售协议及根据配售协议进行H股配售（以下简称"本次配售"）。本公告 中所用词汇的含义除另有定义外，与配售公告所界定者相同。 公司获悉，本次配售已于2025年6月12日完成，科伦博泰按331.8港元/股的配 售价格向不少于6名的承配人配售合计5,918,000股H股，配售所得款项净额约为 19.43亿港元，资金用途见配售公告披露内容。 本次配售完成后，科伦博泰的股份总数为233,185,969股，其中公司及全资子 公司科伦国际发展有限公司合计直接持有科伦博泰约53.41%股份，公司仍为科伦 博泰的控股股东。本次配售不存在损害公司及全体股东利益的情形。 特此公告。 证券代码：002422 证券简称：科伦药业 公告编号：2025-049 四川科伦药业股份有限公司 关于控股子公司科伦博泰完成根据一般性授权配售股份的公告 ...

Core Viewpoint - Sichuan Kelun Pharmaceutical Co., Ltd. announced that its subsidiary, Sichuan Kelun Botai Biopharmaceutical Co., Ltd., received breakthrough therapy designation from the National Medical Products Administration (NMPA) for its TROP2 ADC product, sac-TMT, in combination with PD-L1 monoclonal antibody, Tagolizumab, for the first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without driver gene mutations [2][3]. Group 1: Product and Clinical Development - Sac-TMT is a novel TROP2 ADC developed by Kelun Botai, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), and gynecological tumors [3][5]. - The drug utilizes a new linker and has a drug-antibody ratio (DAR) of 7.4, employing a topoisomerase I inhibitor as an effective payload to induce DNA damage in tumor cells [3][5]. - Sac-TMT has previously received four other breakthrough therapy designations for various indications, including triple-negative breast cancer (TNBC) and EGFR mutation-positive NSCLC [3][4]. Group 2: Regulatory and Market Position - Sac-TMT is the first domestically developed ADC with global intellectual property rights and the first TROP2 ADC approved for lung cancer indications globally [5]. - The drug has already been approved for two indications in China, including treatment for advanced TNBC and EGFR mutation-positive NSCLC after prior treatment [4][5]. - Kelun Botai has initiated eight registration clinical studies in China, while Merck has started 14 ongoing global Phase III clinical studies for sac-TMT in various cancer types [5]. Group 3: Collaborations and Partnerships - In May 2022, Kelun Botai granted Merck exclusive rights to develop, use, manufacture, and commercialize sac-TMT outside Greater China [4]. - Tagolizumab, the PD-L1 monoclonal antibody used in combination with sac-TMT, is the first approved PD-L1 antibody for first-line treatment of nasopharyngeal carcinoma in China [6].

Investment Rating - The report recommends a "Buy" rating for multiple companies in the pharmaceutical sector, including Junshi Biosciences, Hualing Pharmaceutical-B, and others [3]. Core Insights - The pharmaceutical sector has outperformed the market, with a focus on the potential of innovative drugs and the CD73 target in cancer immunotherapy [4][5]. - The report highlights the promising clinical progress of CD73 inhibitors, with several products in various stages of clinical trials [21][25]. Summary by Sections Industry Investment Rating - The report provides a list of recommended companies with "Buy" and "Hold" ratings, indicating strong investment potential in the pharmaceutical sector [3]. Industry Performance - The pharmaceutical sector rose by 1.13%, outperforming the CSI 300 index by 0.25 percentage points, with innovative drugs and vaccines leading the performance [5][32]. Company Dynamics - Companies such as Lepu Medical and Sunshine Nuohua have made significant announcements regarding new product approvals and clinical trial progress, indicating a robust pipeline and growth potential [33][34]. Industry Trends - The report discusses the increasing focus on innovative drugs and the impact of regulatory changes on the pharmaceutical landscape, suggesting a shift towards high-efficiency business models in the industry [31][40].